- Latest available (Revised)
- Original (As adopted by EU)
Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
This version of this Regulation was derived from EUR-Lex on IP completion day (31 December 2020 11:00 p.m.). It has not been amended by the UK since then. Find out more about legislation originating from the EU as published on legislation.gov.uk.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Nafcillin | Nafcillin | Bovine | 300 μg/kg | Muscle | For intramammary use only |
300 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
30 μg/kg | Milk’ |
‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Cefoperazone | Cefoperazone | Bovine | 50 μg/kg | Milk’ |
‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Tiamulin | Sum of metabolites that may be hydrolysed to 8-α-hydroxymutilin | Turkey | 100 μg/kg | Muscle | |
100 μg/kg | Skin and fat | ||||
300 μg/kg | Liver’ |
‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Lincomycin | Lincomycin | Ovine | 100 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
150 μg/kg | Milk | ||||
Porcine | 100 μg/kg | Muscle | |||
50 μg/kg | Skin and fat | ||||
500 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
Chicken | 100 μg/kg | Muscle | |||
50 μg/kg | Skin and fat | ||||
500 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
50 μg/kg | Eggs’ |
‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Netobimin | Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole | [X1Bovine, ovine] | 100 μg/kg | Muscle | For oral use only |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk’ |
Editorial Information
X1 Substituted by Corrigendum to Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 118 of 27 April 2001).
‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Phoxim | Phoxim | Ovine | 50 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
400 μg/kg | Fat | ||||
50 μg/kg | Kidney | ||||
Porcine | 20 μg/kg | Muscle | |||
700 μg/kg | Skin and fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney’ |
[X1‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Cyhalothrin | Cyhalothrin (sum of isomers) | Bovine | 500 μg/kg | Fat | Further provisions in Council Directive 94/29/EC are to be observed |
50 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
[X2Cyfluthrin | Cyfluthrin (sum of isomers) | Bovine, caprine | 50 μg/kg | Fat | |
10 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
20 μg/kg | Milk | Further provisions in Council Directive 94/29/EC are to be observed’ ] ] |
Editorial Information
X2 Substituted by Corrigendum to Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Union L 118 of 27 April 2001).
‘Pharmacologically active substance(s) | Animal species | Other provisions |
---|---|---|
Linear alkyl benzene sulphonic acids with alkyl chain lengths ranging from C9 to C13, containing less than 2,5 % of chains longer than C13 | Bovine | For topical use only’ |
‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Cefacetrile | Cefacetrile | Bovine | 125 μg/kg | Milk | Provisional MRLs expire on 1.1.2002 For intramammary use only’ |
‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Oxolinic acid | Oxolinic acid | Bovine | 100 μg/kg | Muscle | Provisional MRLs expire on 1.1.2003 Not for use in animals from which milk is produced for human consumption |
50 μg/kg | Fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney | ||||
Porcine | 100 μg/kg | Muscle | |||
50 μg/kg | Skin and fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney | ||||
Chicken | 100 μg/kg | Muscle | |||
50 μg/kg | Skin and fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney | ||||
50 μg/kg | Eggs | ||||
Fin fish | 300 μg/kg | Muscle and skin in natural proportions’ |
‘Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Permethrin | Permethrin (sum of isomers) | Chicken, porcine | 50 μg/kg | Muscle | Provisional MRLs expire on 1.1.2003 |
500 μg/kg | Skin and fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
Bovine, caprine | 50 μg/kg | Muscle | Provisional MRLs expire on 1.1.2003 | ||
500 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
50 μg/kg | Milk | Further provisions in Commission Directive 98/82/EC are to be observed (OJ L 290, 29.10.1998, p. 25) | |||
Chicken | 50 μg/kg | Eggs | Provisional MRLs expire on 1.1.2003’ |
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: